Published in J Virol on May 14, 2014
Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial. PLoS Comput Biol (2015) 1.70
Are Clade Specific HIV Vaccines a Necessity? An Analysis Based on Mathematical Models. EBioMedicine (2015) 0.92
Sex, age, race and intervention type in clinical studies of HIV cure: a systematic review. AIDS Res Hum Retroviruses (2015) 0.86
HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition. Sci Transl Med (2015) 0.81
Recent developments in clinical trial designs for HIV vaccine research. Hum Vaccin Immunother (2015) 0.77
Conserved epitopes on HIV-1, FIV and SIV p24 proteins are recognized by HIV-1 infected subjects. Hum Vaccin Immunother (2015) 0.77
FCGR2C Polymorphisms Associated with HIV-1 Vaccine Protection Are Linked to Altered Gene Expression of Fc-γ Receptors in Human B Cells. PLoS One (2016) 0.76
Complex immune correlates of protection in HIV-1 vaccine efficacy trials. Immunol Rev (2017) 0.76
A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trial. Vaccine (2016) 0.75
CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participants. PLoS One (2014) 0.75
Dynamics and Correlates of CD8 T-Cell Counts in Africans with Primary Human Immunodeficiency Virus Type 1 Infection. J Virol (2016) 0.75
Peptide Targeted by Human Antibodies Associated with HIV Vaccine-Associated Protection Assumes a Dynamic α-Helical Structure. PLoS One (2017) 0.75
Sanger and Next-Generation Sequencing data for characterization of CTL epitopes in archived HIV-1 proviral DNA. PLoS One (2017) 0.75
Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol (1973) 47.81
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis (2011) 14.93
Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 12.98
Follicular helper CD4 T cells (TFH). Annu Rev Immunol (2011) 12.50
Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med (1996) 10.49
CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med (2006) 10.34
Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis (2005) 10.20
Variation in protection by BCG: implications of and for heterologous immunity. Lancet (1995) 9.66
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature (2011) 9.30
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet (2008) 8.37
HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science (1999) 8.11
Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis (2006) 7.98
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med (2009) 6.22
Correlates of protection induced by vaccination. Clin Vaccine Immunol (2010) 5.21
Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity (2013) 4.82
NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS One (2007) 3.99
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature (2012) 3.83
Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. PLoS Pathog (2012) 3.35
Immune clearance of highly pathogenic SIV infection. Nature (2013) 3.15
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis (2012) 2.89
Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med (1989) 2.77
HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome. Sci Transl Med (2012) 2.72
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med (2011) 2.71
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A (2013) 2.69
Two complementary methods for predicting peptides binding major histocompatibility complex molecules. J Mol Biol (1997) 2.57
Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med (2014) 2.47
Control of human immunodeficiency virus type 1 is associated with HLA-B*13 and targeting of multiple gag-specific CD8+ T-cell epitopes. J Virol (2007) 2.26
Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nat Rev Immunol (2010) 2.20
Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries. Immunome Res (2008) 2.07
TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection. Nat Immunol (2012) 2.04
Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J Infect Dis (2004) 2.01
Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLoS One (2014) 1.97
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses (2012) 1.94
Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines. Nat Med (2012) 1.86
Vaccine-induced CD8+ T cells control AIDS virus replication. Nature (2012) 1.78
NetMHCIIpan-2.0 - Improved pan-specific HLA-DR predictions using a novel concurrent alignment and weight optimization training procedure. Immunome Res (2010) 1.78
Cross-reactive influenza virus-specific CD8+ T cells contribute to lymphoproliferation in Epstein-Barr virus-associated infectious mononucleosis. J Clin Invest (2005) 1.76
The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol (2012) 1.75
Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J Acquir Immune Defic Syndr (2007) 1.73
Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest (2011) 1.73
The contribution of HLA class I antigens in immune status following two doses of rubella vaccination. Hum Immunol (2004) 1.70
Majority of peptides binding HLA-A*0201 with high affinity crossreact with other A2-supertype molecules. Hum Immunol (2001) 1.68
Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PLoS One (2013) 1.65
PyPop update--a software pipeline for large-scale multilocus population genomics. Tissue Antigens (2007) 1.60
Measurement of MHC/peptide interactions by gel filtration. Curr Protoc Immunol (2001) 1.60
Structure-based prediction of binding peptides to MHC class I molecules: application to a broad range of MHC alleles. Protein Sci (2000) 1.58
Merck Ad5/HIV induces broad innate immune activation that predicts CD8⁺ T-cell responses but is attenuated by preexisting Ad5 immunity. Proc Natl Acad Sci U S A (2012) 1.46
Relationship between functional profile of HIV-1 specific CD8 T cells and epitope variability with the selection of escape mutants in acute HIV-1 infection. PLoS Pathog (2011) 1.42
Learning MHC I--peptide binding. Bioinformatics (2006) 1.41
Demographic processes affect HIV-1 evolution in primary infection before the onset of selective processes. J Virol (2011) 1.41
Localization of CD4+ T cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processing. Proc Natl Acad Sci U S A (2001) 1.39
Dengue and dengue haemorrhagic fever: implications of host genetics. FEMS Immunol Med Microbiol (2006) 1.28
HLA class I binding of HBZ determines outcome in HTLV-1 infection. PLoS Pathog (2010) 1.28
Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines. J Infect Dis (2004) 1.28
Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees. J Virol (2013) 1.26
Immunogenetics of seasonal influenza vaccine response. Vaccine (2008) 1.25
Replication of rubella vaccine population genetic studies: validation of HLA genotype and humoral response associations. Vaccine (2009) 1.17
HLA-associated clinical progression correlates with epitope reversion rates in early human immunodeficiency virus infection. J Virol (2008) 1.13
Genetic polymorphisms in host antiviral genes: associations with humoral and cellular immunity to measles vaccine. Vaccine (2011) 1.12
Estimation of Stratified Mark-Specific Proportional Hazards Models with Missing Marks. Scand Stat Theory Appl (2012) 1.12
Vaccinomics and personalized vaccinology: is science leading us toward a new path of directed vaccine development and discovery? PLoS Pathog (2011) 1.10
Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome. Retrovirology (2012) 1.10
Genome-wide genetic associations with IFNγ response to smallpox vaccine. Hum Genet (2012) 1.08
Sieve analysis in HIV-1 vaccine efficacy trials. Curr Opin HIV AIDS (2013) 1.07
Consistency of HLA associations between two independent measles vaccine cohorts: a replication study. Vaccine (2012) 1.03
MRKAd5 HIV-1 Gag/Pol/Nef vaccine-induced T-cell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral load. PLoS One (2012) 1.03
Case-only method for cause-specific hazards models with application to assessing differential vaccine efficacy by viral and host genetics. Biostatistics (2013) 1.02
Therapeutic DNA vaccine induces broad T cell responses in the gut and sustained protection from viral rebound and AIDS in SIV-infected rhesus macaques. PLoS One (2012) 1.01
Variation in vaccine response in normal populations. Pharmacogenomics (2004) 1.00
Loss of anti-viral immunity by infection with a virus encoding a cross-reactive pathogenic epitope. PLoS Pathog (2012) 0.99
HLA class I and II alleles and haplotypes in ethnic Northeast Thais. Tissue Antigens (2010) 0.97
HLA-F and MHC-I open conformers cooperate in a MHC-I antigen cross-presentation pathway. J Immunol (2013) 0.92
HIV-1 envelope resistance to proteasomal cleavage: implications for vaccine induced immune responses. PLoS One (2012) 0.92
Protease cleavage sites in HIV-1 gp120 recognized by antigen processing enzymes are conserved and located at receptor binding sites. J Virol (2009) 0.89
Race and sex-based differences in cytokine immune responses to smallpox vaccine in healthy individuals. Hum Immunol (2013) 0.88
High-dimensional gene expression profiling studies in high and low responders to primary smallpox vaccination. J Infect Dis (2012) 0.88
Host genetics of HIV acquisition and viral control. Annu Rev Med (2012) 0.87
HIV-1 envelope T cell epitope "hotspots " among mice and humans and among CD4+ and CD8+ T cell subpopulations. AIDS Res Hum Retroviruses (2007) 0.82
Orchestrating high-throughput genomic analysis with Bioconductor. Nat Methods (2015) 6.11
Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial. PLoS Comput Biol (2015) 1.70
Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol Ther (2013) 1.61
Measurement of MHC/peptide interactions by gel filtration or monoclonal antibody capture. Curr Protoc Immunol (2013) 1.24
COMPASS identifies T-cell subsets correlated with clinical outcomes. Nat Biotechnol (2015) 1.14
The contribution of cell cycle to heterogeneity in single-cell RNA-seq data. Nat Biotechnol (2016) 0.87
Validation of an oligonucleotide ligation assay for quantification of human immunodeficiency virus type 1 drug-resistant mutants by use of massively parallel sequencing. J Clin Microbiol (2014) 0.84
Dendritic cells restore CD8+ T cell reactivity to autologous HIV-1. J Virol (2014) 0.82
HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders. Nat Med (2015) 0.80
Adjuvants: tailoring humoral immune responses. Curr Opin HIV AIDS (2017) 0.76
Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. PLoS Pathog (2017) 0.76
Fitness-Balanced Escape Determines Resolution of Dynamic Founder Virus Escape Processes in HIV-1 Infection. J Virol (2015) 0.76
Effective Cytotoxic T Lymphocyte Targeting of Persistent HIV-1 during Antiretroviral Therapy Requires Priming of Naive CD8+ T Cells. MBio (2016) 0.75
Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to DENV4 Infection and Vaccination. J Virol (2016) 0.75
CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participants. PLoS One (2014) 0.75
Adenovirus Serotype 5 Vaccination Results in Suboptimal CD4 T Helper 1 Responses in Mice. J Virol (2017) 0.75
DNA priming increases frequency of T-cell responses to a VSV HIV vaccine with specific enhancement of CD8(+) T-cell responses by IL-12 pDNA. Clin Vaccine Immunol (2017) 0.75
Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments. J Virol (2017) 0.75
Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. Stat Commun Infect Dis (2017) 0.75
Origin and differentiation of human memory CD8 T cells after vaccination. Nature (2017) 0.75
DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial. J Clin Invest (2019) 0.75
HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces Gp41 Antibody Immunodominance in Rhesus Macaques. J Virol (2017) 0.75